Results 171 to 180 of about 2,290 (211)
Some of the next articles are maybe not open access.
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
Drugs, 2011The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire +2 more sources
Highlight: Dipeptidyl peptidase 4 and related proteins
Biological Chemistry, 2011No abstract ...
Torsten, Hoffmann, Hans-Ulrich, Demuth
openaire +2 more sources
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Diabetes & Metabolism, 2018Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular ...
Scheen, André, DELANAYE, Pierre
openaire +3 more sources
Effect of dipeptidyl peptidase‐4 inhibitors on complement activation
Diabetes/Metabolism Research and Reviews, 2020AbstractBackgroundAdverse activation of the complement cascade in the innate immune system appears to be involved in development of vascular complications in diabetes. Dipeptidyl peptidase‐4 (DPP‐4) is a cell surface serine protease expressed in a variety of tissues.
Ingeborg T. Hoffmann‐Petersen +7 more
openaire +3 more sources
Dipeptidyl peptidase-4 inhibition and renoprotection
Current Opinion in Nephrology and Hypertension, 2017This article analyzes the potential beneficial effects of dipeptidyl peptidase (DPP)-4 inhibitors on renal diseases.The pathological significance of DPP-4, either dependent or independent on catalytic activities, on renal diseases has been reported in preclinical studies.
Yuta, Takagaki +2 more
openaire +2 more sources
Dipeptidyl peptidase-4 inhibitors
2016Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
openaire +1 more source
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...Kimberly C. McKeirnan +1 more
openaire +2 more sources
Periostin and Dipeptidyl Peptidase-4
Immunology and Allergy Clinics of North America, 2018Claire Emson +3 more
openaire +1 more source